Research and Data Sample Clauses

Research and Data. In order to support efforts for closing the online achievement gap, the CVC-OEI may establish partnerships with various research organizations with a goal of gathering data to support program efficacy. As such, Consortium colleges may be invited to participate in selected research projects. Participation may include but is not limited to allowing CVC-OEI affiliated researchers access to campus and/or district data, as needed, encouraging participation in CVC-OEI focus groups, surveys, as well as closed beta testing of select student support technology tools and data analytics projects. As required, CVC-OEI will facilitate agreements required to ensure compliance with data security and privacy requirements. CVC-OEI agrees to provide Participating College with access to comprehensive reporting and data, as appropriate, to inform effective student success strategies for closing the online achievement gap as well as improve overall online student completion rates.
AutoNDA by SimpleDocs
Research and Data. In order to support efforts for closing the online achievement gap, the CVC-OEI may establish partnerships with various research organizations with a goal of gathering data to support program efficacy. As such, Consortium colleges may be invited to participate in selected research projects. Participation may include but is not limited to allowing CVC-OEI affiliated researchers access to campus and/or district data, as needed, encouraging participation in CVC-OEI focus groups, surveys, as well as closed beta testing of select student support technology tools and data analytics projects. As required, CVC-OEI will facilitate agreements required to ensure compliance with data security and privacy requirements. CVC-OEI agrees to provide Participating College with findings from any research conducted under this provision. To successfully accomplish the goals of the CVC-OEI and support the new CVC Exchange, the Participating College agrees to an operational exchange of data between additional Participating Colleges as needed to support student transaction processing. An Operating Level Agreement is incorporated to establish the principles by which data is exchanged to facilitate the necessary operations of the CVC-OEI and to do so securely and with sufficient provisions to protect student privacy and in accordance with governing policies. These principles are incorporated as Exhibit 1 and can be accessed at xxxxx://xxx.xxx/operatinglevelagreement/.
Research and Data. What existing marketing research do you have; are there any gaps, and if so, where? - The South Dakota Governor’s Office of Economic Development is currently reviewing RFP responses for an up-to-date marketing research project. Does the Governor’s Office have first-party data available to be used for paid media campaigns? - The South Dakota Governor’s Office of Economic Development has some first-party data, but is limited.
Research and Data. Any and all data, software, algorithms, medical protocols and applications generated for Use related to the Detection Unit (collectively, the "Data"), whether undertaken by TMI and CTI jointly, by TMI separately or jointly with an authorized third party, shall be owned by TMI, owned by CTI if developed by CTI, but shall be made available and licensed to the other Party for use without royalty and for sublicense with a fair royalty. The Parties agree, if necessary, to secure all appropriate consents, acknowledgments, releases and authorizations to this end, such as confidentiality and noncompete covenants in all agreements with systems integrators. All Federal and State laws applicable to this provision shall be fully complied with by the parties, including without limitation all patient medical records laws, rules and regulations.
Research and Data. The Office for Social Inclusion will continue its work on developing a data strategy to ensure that robust and reliable data is available in a timely manner to enable effective monitoring of policies to combat poverty and social exclusion. The availability of comprehensive data will also assist the formulation of effective evidence-based policies. The Office will also work on the further development of indicators and measures to facilitate the monitoring and evaluation process. The implementation of the National Health Information Strategy recommendations in respect of the use of a system of a unique patient identifier and the development of an electronic healthcare record will contribute to establishing a holistic picture of individual needs as well as providing data to aid the development of high quality and cost effective health services to address those needs. The development of a system of unique identification for the health service will be considered in the context of a public service wide approach to the development and use of unique identifiers, proposals for which will include discussion with the health sector. This process will inform the preparation of a Health Information Bill which will provide a legislative framework for health Information governance. The parties to this agreement share a vision of an Ireland which provides the supports, where necessary, to enable older people to maintain their health and well-being, as well as to live active and full lives, in an independent way in their own homes and communities for as long as possible. To achieve this vision, the Government and social partners will work together over the next ten years towards the following long-term goals for older people in Ireland in the context of increased longevity and greater possibilities and expectations for quality of life of older people: • Every older person would be encouraged and supported to participate to the greatest extent possible in social and civic life. • Every older person would have access to an income which is sufficient to sustain an acceptable standard of living. • Every older person would have adequate support to enable them to remain living independently in their own homes for as long as possible. This will involve access to good quality services in the community, including: health, education, transport, housing and security. • Every older person would, in conformity with their needs and conscious of the high level of disability and disablin...
Research and Data. The results of the first National Disability Survey, together with the data emerging from the Physical and Sensory and Intellectual Disability Databases will further help in monitoring progress in this area. This will also be enhanced by the collection of aggregate data through the implementation of the needs assessment process under the Disability Act 2005. The implementation of the National Health Information Strategy recommendations in respect of the use of a system of a unique patient identifier and the development of an electronic healthcare record will contribute to establishing a holistic picture of individual needs as well as providing data to aid the development of high quality and cost effective health services to address those needs. See Section XX. The National Longitudinal Study of Children will identify, in the first instance, children who have been diagnosed as having a disability by age 9 months, 3 years, 9 years and 13 years. This study will allow for both point prevalence and incidence to be recorded within the child population. Reporting arrangements have been put in place in relation to spending under the multi-annual investment programme and it is intended that the sectoral plan review process would also be used to measure outcomes under the Strategy.

Related to Research and Data

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • Development Services During the term of this Agreement, the Provider agrees to provide to or on behalf of the Port the professional services and related items described in Exhibit A (collectively, the “Development Services”) in accordance with the terms and conditions of this Agreement. The Provider specifically agrees to include at least one Port representative in any economic development negotiations or discussions in which the Provider is involved concerning (i) a port-related business prospect or (ii) a business transaction which will ultimately require Port involvement, financial or otherwise.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

Time is Money Join Law Insider Premium to draft better contracts faster.